| | |
 | | Press Release 7 May 2020 7:00 am CEST Regulated Information |
About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specializedCAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’sCAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate,CYAD-01, an autologous NKG2D-basedCAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developingCYAD-101, an investigational,non-gene edited, allogeneic (donor derived) NKG2D-basedCAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. Celyad has received funding from the Walloon Region (Belgium) to support the advancement of itsCAR-T cell therapy programs.
For more information, please contact:
|
Celyad Filippo Petti, Chief Executive Officer – investors@celyad.com Alexandrine Hazard, Communications & IR Associate – T: +32(0) 10 39 41 58 – communications@celyad.com |
U.S.: LifeSci Advisors Investor Relations: Daniel Ferry – T.: +1 (617) 430 7576 – daniel@lifesciadvisors.com Public Relations: Sara Zelkovic – T.: +1 (646) 876 4933 – sara@lifescicomms.com |
Forward-looking statements
This release may contain forward-looking statements, including statements regarding: the safety and clinical activity ofCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series; statements regarding the ongoing and planned clinical development ofCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series, including the timing of trials, enrolment, data readouts and presentations; the clinical and commercial potential ofCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series; the success of the OptimAb manufacturing system; the ongoing and planned clinical and commercial potential and development of Celyad’s shRNA technology; Celyad’s financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with theCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series product candidates. These results may not be repeated or observed in ongoing or future studies involving theCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our OptimAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval ofCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series in the United States and Europe and subsequent commercial success ofCYAD-01,CYAD-02,CYAD-100 Series andCYAD-200 Series, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing product candidates and statements regarding future revenue, hiring plans, expenses, capital
www.celyad.com | 3
